• Users Online: 257
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 38  |  Issue : 1  |  Page : 42-45

Results of intravenous immunoglobulin use and treatment in the South Province of Turkey


Department of Dermatology, Faculty of Medicine, Kahramanmarasş Sütçü İmam University, Kahramanmarasş, Turkey

Correspondence Address:
Hülya Nazik
Department of Dermatology, Faculty of Medicine, Kahramanmarasş Sütçü İmam University, Kahramanmarasş 46100
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ejdv.ejdv_39_17

Rights and Permissions

Objective In this study, we aimed to evaluate the use of intravenous immunoglobulin (IVIG) in our clinic and investigate the effect of its treatment on diseases in patients with pemphigus. Materials and methods Age, sex, disease, skin biopsy result, duration of illness, treatments received, IVIG adverse effects, and clinical course were recorded by screening medical records of patients with different diagnoses receiving IVIG. The findings were evaluated retrospectively. Findings The total number of cases treated with IVIG was 21. A total of 14 cases were diagnosed as having pemphigus, and three cases were diagnosed as having pyoderma gangrenosum, one (4.8%) case as Sweet syndrome, one (4.8%) case as lichen planus, one (4.8%) case as resistant urticaria, and one (4.8%) case as hyperimmunoglobulin E syndrome. The mean time to start IVIG treatment from diagnosis in patients with pemphigus was 2.62±2.3 years (minimum–maximum: 1–10 years). The mean number of cure IVIG treatment cycles given to patients was 11.38±7.63 (minimum–maximum: 1–30). In patients with pemphigus, a partial remission was achieved with an average cure IVIG treatment cycle of 2.71±3.3 (minimum–maximum: 0–10 cures). In three (21.4%) of the pemphigus cases that received IVIG, the treatment was terminated owing to remission. In pemphigus cases where the treatment was terminated owing to remission, the mean number of IVIG cycles was 12.7±5.9 (minimum–maximum: 6–17). Conclusion IVIG treatment has become a reliable treatment option in our clinic, which is preferred owing to successful treatment results and clinical experience in many different diseases, especially pemphigus.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed135    
    Printed0    
    Emailed0    
    PDF Downloaded41    
    Comments [Add]    

Recommend this journal